Nuvation Bio (NUVB) Expected to Announce Quarterly Earnings on Monday

Nuvation Bio (NYSE:NUVB) is expected to be announcing its Q4 2025 results after the market closes on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $36.8220 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:30 PM ET.

Nuvation Bio Trading Up 0.5%

NUVB opened at $5.47 on Tuesday. Nuvation Bio has a one year low of $1.54 and a one year high of $9.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 8.39. The business has a 50 day simple moving average of $6.98 and a two-hundred day simple moving average of $5.41. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -8.54 and a beta of 1.52.

Insider Buying and Selling at Nuvation Bio

In other news, insider Dongfang Liu sold 150,000 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.82, for a total value of $1,173,000.00. Following the sale, the insider directly owned 18,000 shares of the company’s stock, valued at $140,760. This represents a 89.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 29.93% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Nuvation Bio

Several hedge funds have recently bought and sold shares of the business. Rangeley Capital LLC purchased a new stake in Nuvation Bio in the second quarter worth about $25,000. Parallel Advisors LLC boosted its position in shares of Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after purchasing an additional 2,597 shares in the last quarter. Cetera Investment Advisers purchased a new stake in shares of Nuvation Bio in the 2nd quarter worth approximately $29,000. Captrust Financial Advisors purchased a new stake in shares of Nuvation Bio in the 2nd quarter worth approximately $32,000. Finally, Focus Partners Wealth bought a new position in Nuvation Bio during the 3rd quarter valued at approximately $49,000. Institutional investors own 61.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NUVB. Royal Bank Of Canada upped their target price on Nuvation Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Nuvation Bio in a report on Tuesday, February 10th. Truist Financial set a $13.00 target price on shares of Nuvation Bio in a research report on Tuesday, January 27th. Citizens Jmp set a $10.00 price target on shares of Nuvation Bio in a research report on Thursday, November 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Nuvation Bio presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.